Akorn: the Pharmaceutical Stock You Can’t Afford to Ignore

NEW YORK (TheStreet) -- A San Diego-based biopharmaceutical company is gaining international attention for an experimental Ebola treatment that just saved two lives.

Mapp Biopharmaceutical is that company. Although it might sound like it employs hundreds, it actually employs only nine.

It shipped three vials containing an experimental Ebola drug to two American aid workers in Liberia. It was a last-ditch effort to save their lives while their families were making funeral arrangements back in the U.S. Fortunately, those funerals were canceled.

I know what you may be thinking: What’s the ticker symbol for Mapp Biopharmaceutical? Well, unfortunately Mapp Biopharmaceuticals is not a publicly traded company; it is privately held.

But let’s hear it for the biotech and pharma stocks. These past two to three years have brought some amazing advances in the field of drug discovery and therapeutic medicine.

Drug stocks continue to be one of the best areas in the market. One name that I continue to own in my Aggressive Growth Account is Akorn (AKRX). And this company is actually public, though you may not know much about it.

Akorn, based in Lake Forest, Ill., is a niche generic pharmaceutical company that develops and markets pharmaceuticals in the areas of ophthalmology, hospital drugs and injectables. Stocks like this have been big winners in the past six months. Akorn in particular ranks as a Gunderson Trophy Winner, making it rare and mighty. I have only 10 Trophy Winner stocks in my 3,850 stock universe.

Let’s examine what makes Akorn a Trophy Winner at Gunderson Capital Management:

Data from Best Stocks Now App

Akorn has a market cap of $3.6 billion. Back in 2010, Akorn traded at $1 per share. Today the stock is at $37 per share. While Akorn may not be a mighty oak quite yet, it is well on its way.

Data from Best Stocks Now App

If you liked this article you might like

Teva, Mylan Seen to Stay on M&A Sidelines

Merger Buzz Drives Akorn to Top of Health Chart in April

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

European Stocks High on French Perfume and Trump Bump

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More